Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The …
Medical - Healthcare Information Services
US, New York [HQ]
Ratios
7 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | 71.46 | 64.43 | 57.39 | 58.72 | 47.57 | 55.83 | 64.66 | |
| Profit Margin | -31.23 | -42.66 | -30.02 | -24.64 | -73.38 | -82.45 | 18.79 | |
| Operating Margin | -34.15 | -41.97 | -45.26 | -56.35 | -80.80 | -82.41 | -81.90 | |
|
EPS Growth
|
- - | -37.21 | 30.51 | -7.32 | -225.00 | -46.85 | 127.14 | |
| EPS USD | -43.00 | -59.00 | -41.00 | -44.00 | -143.00 | -210.00 | 57.00 | |
| Return on Assets (ROA) | -29.97 | -23.54 | -16.54 | -3.57 | -13.38 | -21.67 | 5.07 | |
| Return on Equity (ROE) | 38.34 | 39.72 | 27.51 | -4.27 | -18.17 | -33.31 | 7.42 | |
| Return on Invested Capital (ROIC) | 42.75 | 39.19 | 48.52 | -9.71 | -17.57 | -26.43 | -24.89 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | 9.32 | 1.58 | 10.56 | 16.92 | 15.93 | |
| Debt/Equity | - - | - - | -15.50 | 1.89 | 14.34 | 26.01 | 23.31 | |
| Debt/EBITDA | 63.46 | 320.31 | 25.59 | 222.79 | 33.68 | -17.97 | 19.31 | |
|
Debt/Capitalization
|
- - | - - | -18.34 | 1.85 | 12.54 | 20.64 | 18.91 | |
| Long-Term Debt/Capitalization | - - | - - | -10.52 | 1.14 | 12.26 | 19.06 | 16.83 | |
| Interest Debt per Share USD | - - | - - | 0.23 | 0.20 | 1.13 | 1.64 | 1.78 | |
| Debt Growth | - - | - - | - - | -18.71 | 578.93 | 45.85 | 9.78 | |
| Liquidity | ||||||||
| Current Ratio | 269.69 | 387.67 | 263.30 | 932.97 | 685.29 | 490.80 | 424.76 | |
| Quick Ratio | 258.74 | 378.03 | 247.82 | 926.26 | 676.49 | 478.11 | 417.34 | |
| Cash Ratio | 55.90 | 287.78 | 57.72 | 276.34 | 131.86 | 83.16 | 120.49 | |
| Operating Cash Flow Ratio | - - | - - | - - | - - | - - | -100 | - - | |
| Turnover | ||||||||
| Inventory Turnover | - - | - - | - - | -1,128.27 | -821.06 | -608.46 | - - | |
| Receivables Turnover | 570.68 | 369.79 | 332.36 | 305.54 | 340.14 | 261.91 | 243.13 | |
| Payables Turnover | 987.14 | 854.74 | 1,034.34 | 531.35 | 895.05 | 844.07 | 455.31 | |
|
Asset Turnover
|
95.99 | 55.20 | 55.09 | 14.48 | 18.23 | 26.28 | 26.98 | |
| Fixed Turnover | 1,023.96 | 836.44 | 449.52 | 707.94 | 161.49 | 150.51 | 153.55 | |
| Coverage | ||||||||
| Interest Coverage | - - | - - | - - | - - | - - | -4,970,766.67 | - - | |
| Asset Coverage | - - | - - | 800 | 5,700 | 800 | 500 | 500 | |
| Cash Flow Coverage (CFGR) | - - | - - | -180.06 | 142.44 | -88.48 | -102.74 | 8.20 | |
| EBITDA Coverage | - - | - - | - - | - - | - - | -4,825,900 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.50 | -2.05 | -1.42 | -0.56 | -4.12 | -11.22 | 1.59 | |
|
Price/Earnings (P/E)
|
-6,650.33 | -4,883.22 | -7,055.49 | -17,842.67 | -2,429.21 | -891.64 | 6,310.39 | |
| Price/Earnings Growth (PEG) | - - | -131.24 | 231.26 | -2,438.50 | -10.80 | -19.03 | -49.63 | |
|
Price/Book (P/B)
|
-2,549.77 | -1,939.71 | -1,940.71 | 761.64 | 441.38 | 297.00 | 468.43 | |
| Price/Tangible Book (P/TB) | -2,549.77 | -1,939.71 | -1,940.71 | 761.64 | 441.38 | 297.00 | 468.43 | |
| Price/Sales (P/S) | 2,076.79 | 2,082.95 | 2,118.14 | 4,396.83 | 1,782.65 | 735.12 | 1,185.97 | |
|
Price/Cash Flow (P/CF)
|
-7,556.19 | -5,854.06 | -6,953.14 | 28,362.79 | -3,479.35 | -1,111.46 | 24,519.00 | |
| Price/Free CF (P/FCF) | -6,085.26 | -4,791.36 | -6,495.50 | 33,425.36 | -3,158.98 | -1,041.71 | -87,909.39 | |
| Price/Operating CF (P/OCF) | -7,556.19 | -5,854.06 | -6,953.14 | 28,362.79 | -3,479.35 | -1,111.46 | 24,519.00 |